Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
By Jeffrey L. Anderson, B. Horne, S. Stevens, Amanda Grove, S. Barton, Zachary P. Nicholas, S. F. Kahn, H. May, Kent M. Samuelson, J. Muhlestein and 1 more. 2007
760 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Pharmacology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Precision Medicine, AI, and the Future of Personalized Health Care (2020, background): “The field of precision medicine is providing an equal or even greater influence than AI on the direction of health care(16) and has been doing so for more than a decade.(17) Precision medicine aims to personalize care for every individual.”
- Clinical Pharmacogenetics Implementation consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing (2011, methodology): “care (5mg/day after a load), masked to patients (n=200) and investigators [29].”
- A Systems Approach to Designing Effective Clinical Trials Using Simulations (2012, methodology): “5,21,22 Although providing compelling evidence that pharmacogenetic-based dosing is beneficial, these 3 trials were underpowered to conclusively demonstrate a benefit of pharmacogenetic-guided therapy.”
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose (2009, background): “However this recommendation is not a requirement due to a lack of large trials demonstrating warfarin patient benefit from dose forecasting (though two small trials [21,22] do support such benefit; see also [23–27] for reviews and other trials).”